Abstract
Backgrounds: Targeted therapy is the foundation of personalized medicine in cancer, which is often understood as the right patient using the right drug. Thinking from the viewpoint of determinants during personalized drug treatment, the genetics, epigenetics and metagenomics would provide individual-specific biological elements to characterize the personalized responses for therapy.
Methods: Such personalized determinants should be not only understood as specific to one person, while they should have certain replicate observations in a group of individuals but not all, which actually provide more credible and reproducible personalized biological features. The requirement of detecting personalized determinants is well supported by novel high-throughput sequencing technologies and newly temporal-spatial experimental protocols, which quickly produce the omics big data.
Results: In this mini-review, we would like to give a brief introduction firstly on the advanced drug or drug-like therapy with genetics, epigenetics and metagenomics, respectively, from the viewpoint of personalized determinants; then summarize the computational methods helpful to analyze the corresponding omics data under the consideration of personalized biological context; and particularly focus on metagenomics to discuss current data, method, and opportunity for personalized medicine.
Conclusion: Totally, detecting personalized determinants during drug treatment from omics big data will bring the precision medicine or personalized medicine from concept to application. More and more inspiring biotechnologies, data resources, and analytic approaches will benefit All of US in the near future.
Keywords: Personalized determinants, drug treatment, omics, big data, biomarker, precision medicine.
Current Pharmaceutical Design
Title:Detecting Personalized Determinants During Drug Treatment from Omics Big Data
Volume: 24 Issue: 32
Author(s): Lu Wang, Xiangtian Yu, Chengming Zhang and Tao Zeng*
Affiliation:
- Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology, Chinese Academy Science, Shanghai 200031,China
Keywords: Personalized determinants, drug treatment, omics, big data, biomarker, precision medicine.
Abstract: Backgrounds: Targeted therapy is the foundation of personalized medicine in cancer, which is often understood as the right patient using the right drug. Thinking from the viewpoint of determinants during personalized drug treatment, the genetics, epigenetics and metagenomics would provide individual-specific biological elements to characterize the personalized responses for therapy.
Methods: Such personalized determinants should be not only understood as specific to one person, while they should have certain replicate observations in a group of individuals but not all, which actually provide more credible and reproducible personalized biological features. The requirement of detecting personalized determinants is well supported by novel high-throughput sequencing technologies and newly temporal-spatial experimental protocols, which quickly produce the omics big data.
Results: In this mini-review, we would like to give a brief introduction firstly on the advanced drug or drug-like therapy with genetics, epigenetics and metagenomics, respectively, from the viewpoint of personalized determinants; then summarize the computational methods helpful to analyze the corresponding omics data under the consideration of personalized biological context; and particularly focus on metagenomics to discuss current data, method, and opportunity for personalized medicine.
Conclusion: Totally, detecting personalized determinants during drug treatment from omics big data will bring the precision medicine or personalized medicine from concept to application. More and more inspiring biotechnologies, data resources, and analytic approaches will benefit All of US in the near future.
Export Options
About this article
Cite this article as:
Wang Lu, Yu Xiangtian , Zhang Chengming and Zeng Tao *, Detecting Personalized Determinants During Drug Treatment from Omics Big Data, Current Pharmaceutical Design 2018; 24 (32) . https://dx.doi.org/10.2174/1381612824666181106102111
DOI https://dx.doi.org/10.2174/1381612824666181106102111 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The State-of-Art in Angiogenic Properties of Latex from Different Plant Species
Current Angiogenesis (Discontinued) Critical Review of Malondialdehyde Analysis in Biological Samples
Current Pharmaceutical Analysis Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Occurrence and Biological Activities of Eremophilane-type Sesquiterpenes
Mini-Reviews in Medicinal Chemistry Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation
Anti-Cancer Agents in Medicinal Chemistry A Cross Sectional Study of Tumors Using Bio-Medical Imaging Modalities
Current Medical Imaging Potential Use of Food Protein-Derived Peptides in the Treatment of Inflammatory Diseases
Protein & Peptide Letters Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers Chemical Constituents and Biological Activity of Chinese Medicinal Herb ‘Xihuangcao’
Combinatorial Chemistry & High Throughput Screening Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases
Current Pharmaceutical Design Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry Molecular Dynamics in Esophageal Adenocarcinoma: Who’s in Control?
Current Cancer Drug Targets Proteinase-Activated Receptor-2: Physiological and Pathophysiological Roles
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Fighting Type-2 Diabetes: Present and Future Perspectives
Current Medicinal Chemistry miR-4295 Promotes the Malignant Progression of Gastric Cancer <i>via</i> Targeting PTEN
Combinatorial Chemistry & High Throughput Screening